• news and publications | Enterprise Therapeutics | Treatment of respiratory diseases

PUBLICATIONS, NEWS & EVENTS

Building in vivo potency and duration of action and into a novel inhaled ENaC blocker, ETD001, presented at the European Cystic Fibrosis Society Basic Science Meeting, Loutraki, Greece, March 2018

Inhaled drugs are typically cleared very rapidly from the airway…
March 2, 2018/by admin

Identifying pathways regulating goblet cell metaplasia: phenotypic screening with bronchospheres, presented at the European Cystic Fibrosis Society Basic Science Meeting, Loutraki, Greece, March 2018

It is widely accepted that the composition of mucus in the CF…
March 1, 2018/by admin

The discovery of novel regulators of airway anion secretion, oral communication at the UK Cystic Fibrosis Trust Conference, Nottingham, UK, September 2017

September 1, 2017/by admin

The discovery of potentiators of the calcium activated chloride channel, TMEM16A, oral communication at the Cystic Fibrosis Foundation Research Conference, Stevenson, USA, June 2017

June 1, 2017/by admin

Enterprise Therapeutics receives funding from Cystic Fibrosis Trust

Award will support research into the use of bronchosphere technology…
April 5, 2017/by admin

The discovery of novel TMEM16A potentiator compounds, presented at the Gordon research Conference, “Mucus & Mucociliary interactions”, Galveston, USA, February 2017

It is widely accepted that the composition of mucus in the CF…
February 1, 2017/by admin

Enterprise Therapeutics Announces £4 million ($5 million USD) Fundraising

Brighton, UK – 10th November, 2016: Enterprise Therapeutics…
November 10, 2016/by admin

Enterprise Therapeutics appoints Dr John Ford as CEO

Brighton, UK – October 17, 2016 - Enterprise Therapeutics Ltd,…
October 17, 2016/by admin

Flagellin-induces a hypersecretory phenotype in primary human bronchial epithelial cells, presented at North America Cystic Fibrosis Conference, Orlando, October 2016

The TLR5-agonist flagellin (FLG) is the key protein component…
October 1, 2016/by admin

Pharmacological characterisation of TMEM16A regulators, presented at The 13th European Cystic Fibrosis Basic Science Conference, Pisa, Italy, March 2016

TMEM16A was recently identified as a calcium-activated chloride…
March 2, 2016/by admin

Flagellin-induces a hypersecretory phenotype in primary human bronchial epithelial cells, presented at The 13th European Cystic Fibrosis Basic Science Conference, Pisa, Italy, March 2016

A screen of microbial-derived products using a 3D model of the…
March 1, 2016/by admin

New drug discovery company announces additional funding to tackle chronic respiratory disease

Brighton, Sussex, May 20th 2015 - ENTERPRISE THERAPEUTICS Ltd,…
May 20, 2015/by admin

Enterprise is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity – the company plans to initiate clinical trials in 2019.

Scientific Strategy

Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.

Learn more

Pipeline

Enterprise has developed a pipeline of novel low molecular weight compounds with first in class potential – our most advanced compounds, which target ion channels in the airway epithelium are expected to enter human trials in late 2019.

Learn more